Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.57 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000689 | 0.89 | MAPT (0.53) | CHEK1CHEK2HTR7PIM2 | |
| SCHEMBL4995136 | 0.88 | CHEK1 (0.67) | CHEK1CHEK2MKNK1MKNK2PIM2 | |
| SCHEMBL4996158 | 0.86 | CHEK1 (0.57) | CHEK1CHEK2HTR1AMKNK1MKNK2 | |
| SCHEMBL5000893 | 0.85 | ABCG2 (0.52) | HTR1AHTR7PIM2GAAGFER | |
| SCHEMBL4993619 | 0.84 | DHFR (0.46) | PIM2GAAGFERDHFR | |
| SCHEMBL5000830 | 0.84 | MEN1 (0.45) | HTR1AHTR2AHTR7HTR6GAA | |
| SCHEMBL5003018 | 0.83 | PIM2 (0.43) | HTR1AHTR2AHTR7HTR6PIM2 | |
| SCHEMBL5002823 | 0.83 | CHEK1 (0.67) | CHEK1CHEK2PIM2 | |
| SCHEMBL5002971 | 0.83 | PIM2 (0.50) | PIM2 | |
| SCHEMBL5000803 | 0.81 | THRB (0.44) | PIM2GAAGFERDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | claimed |
| EP-1694670-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC Biotech AG (DE) | 2006-08-30 | — | — | EP | claimed |
| WO-2005058876-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC BIOTECH AG (DE) | 2005-06-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | PRNP, PSEN1, PPP5C | CHEK1 1668/4885CHEK2 1049/4885HTR1A 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.